Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
BACKGROUND C-reactive protein ( CRP ) levels are associated with cardiovascular risk . We assessed the hypothesis that atorvastatin might have anti-inflammatory effects in acute coronary syndromes ( ACS ) as shown by CRP reduction . METHODS This study was a prospect i ve , r and omized , double-blind , placebo-controlled study of 90 consecutive patients admitted within 48 hours of onset of ACS with CRP levels > or = 1.4 mg/dL. Patients were assigned to atorvastatin 40 mg daily or placebo over 30 days . C-reactive protein levels , lipid profiles , serum fibrinogen , white cell count , and erythrocyte sedimentation rate were measured at entry , hospital discharge , and 1 month later . RESULTS Baseline clinical characteristics did not differ between  atorvastatin and placebo groups ( mean age 59.3 + /- 13.4 vs 61.1 + /- 11.5 , P = ns ) ; myocardial infa rct ion 52.3 % versus 67.4 % ( P = ns ) . In both groups , median baseline CRP levels were comparable ( 5.97 + /- 6.2 vs 4.64 + /- 4.2 mg/dL , P = ns ) . C-reactive protein levels were lower in the atorvastatin group versus control group at discharge ( 1.68 + /- 1.65 vs 4.12 + /- 4.18 mg/dL ) and at 30 days ( 0.50 + /- 0.71 vs 2.91 + /- 2.68 mg/dL , both P < .0001 ) . C-reactive protein levels significantly decreased from baseline to discharge and 1 month later in placebo and atorvastatin groups ( both P < .0001 ) ; however , the reduction was greater in the atorvastatin group ( 62 % vs 11 % at discharge [ P < .0001 ] ; 84 % vs 30 % at 1 month [ P < .0001 ] ) . In addition , atorvastatin was associated with a reduction in total and low-density lipoprotein cholesterol and erythrocyte sedimentation rate at discharge and at 30 days ( P < .0001 for all comparisons ) . No correlation was found between changes in CRP and cholesterol levels . CONCLUSIONS C-reactive protein levels in ACS were rapidly reduced with atorvastatin . These data provide evidence that statins have fast and early anti-inflammatory effects in addition to lipid-lowering effects in ACS
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .